$3.95−$0.1200 (−2.95%) on the dayAs of the close; data may be delayed.
MNKD price, last 12 months
$6.21$2.28$3.95
Daily closes over the last 260 trading sessions: −29.8%. Highest close $6.21 on , lowest $2.28 on . Market data may be delayed.
Key stats
Previous close
$4.07
Open
$4.07
Day range
$3.89 – $4.08
52-week range
$2.23 – $6.51
Volume
4.1M
Avg volume (20 days)
3.4M
Market cap
$1.3B
Performance
1W−6.8%
1M+20.3%
3M−5.4%
6M+13.9%
YTD−32.1%
1Y−23.0%
vs S&P 500, 1Y−27.1 pts
Technicals and fundamentals
About Mannkind Corporation
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Chart MNKD with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full MNKD chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)5.3%average true range, % of price
52w low $2.2352w high $6.51
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)24.4
PEG4.39
Price / sales3.03
Price / book−33.19
EV / EBITDA—
Company figures as of Nov 20, 2026.
Analysts
ConsensusStrong buy1.2 on 1 (strong buy) to 5 (strong sell)
Analysts9
Average target$8.33+116.5% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Feb 25, 2027 (in 96 days)A year after its Feb 26, 2026 results release; the last came Nov 5, 2026. An estimate from its SEC filings, not a date the company announced.
Dividends & splits
No dividends on record.
Splits
Mar 3, 20171-for-5 (reverse)
Seasonality
-5.4
J
-12.2
F
-0.6
M
-2.9
A
+16.6
M
-1.3
J
+1.2
J
+7.9
A
-2.2
S
+4.6
O
+2.5
N
+1.7
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
+2
−43
−25
+16
+33
+13
−8
+3
−3
−10
−38%
2025
−10
−8
−6
+0
−18
−10
+1
+21
+17
+4
−4
+6
−12%
2024
−8
+23
+10
−9
+14
+12
+10
+9
+0
+12
−4
−5
+77%
2023
+4
−3
−22
−6
+21
−12
+12
+1
−10
+4
−16
+1
−31%
2022
−15
−30
+40
−15
+34
−9
−9
+6
−15
+9
+38
+13
+21%
2021
+8
−2
−6
0%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
The company is actively participating in industry conferences and presenting on innovation in chronic respiratory diseases, demonstrating engagement with investors and the medical community. The announcement highlights their focus on addressing serious unmet medical needs and their expertise in drug-device combinations, which suggests confidence in their pipeline and market position.
Company announced successful clinical data presentations supporting its recently FDA-approved Furoscix ReadyFlow product, demonstrating IV-equivalent efficacy and flexible administration options. The approval and launch represent significant commercial milestones for the company's cardiometabolic portfolio, with potential to expand treatment opportunities in outpatient settings.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.